Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 20/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19794565 | 0.88 | GRM4 (0.74) | GRM4CYP1A2CYP2C19 | |
| SCHEMBL19794678 | 0.88 | GRM4 (0.74) | GRM4CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL19794531 | 0.88 | GRM4 (0.72) | GRM4CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL19794787 | 0.86 | GRM4 (1.00) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19794674 | 0.84 | GRM4 (0.75) | GRM4CYP1A2CYP2C19 | |
| SCHEMBL19794684 | 0.84 | GRM4 (0.69) | GRM4CYP1A2CYP2C19 | |
| SCHEMBL19794576 | 0.83 | GRM4 (0.62) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19794648 | 0.80 | GRM4 (0.52) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19794730 | 0.79 | GRM4 (0.72) | GRM4CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL19801403 | 0.78 | GRM4 (0.53) | GRM4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180022745-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180022745-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | GRIA4, GRM4, GRIK4 | GRM4 2/4885CYP1A2 1511/4885CYP2C19 1678/4885 |
| US-20180022745-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIA4, GRM4, GRIK4 | GRM4 2/4885CYP1A2 1511/4885CYP2C19 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.